摘要
目的探究血清miR-122联合肿瘤标志物在慢性乙肝病毒感染肝硬化及早期肝癌中的诊断价值。方法选取2016年7月-2019年10月于滨州市滨城区市立医院进行诊治的慢性乙肝、肝硬化及早期肝癌患者分别为65例、54例、52例为研究对象,所有患者均进行血清肿瘤标志物甲胎蛋白(Alphafetoprotein,AFP)、癌胚抗原(Carcinoembryonic antigen,CEA)检测,qPCR检测血清微小miR-122(microRNA-122,miR-122)水平。分析三者对肝硬化、早期肝癌诊断的价值。结果肝癌组患者中的AFP、CEA分别为(98.64±13.94)ng/ml、(28.86±2.05)ng/ml高于肝硬化组(34.60±11.84)ng/ml、(11.36±2.31)ng/ml和乙肝组(18.38±8.39)ng/ml、(3.57±1.52)ng/ml),肝硬化组患者的肿瘤标志物水平较乙肝组升高(P<0.05)。肝癌组患者血清中的miR-122低于肝硬化组和乙肝组(P<0.001),硬化组患者miR-122也低于乙肝组(P<0.001)。ROC曲线结果显示,对于肝硬化诊断miR-122联合肿瘤标志物检测的诊断效能(AUC=0.813;灵敏度为85.12%;特异性为70.18%)高于肿瘤标志物、miR-122单独检测的效能(P<0.001)。对于早期肝癌诊断miR-122联合肿瘤标志物检测的诊断效能(AUC=0.866;灵敏度为91.23%;特异性为77.19%)高于肿瘤标志物、miR-122单独检测的效能(P<0.001)。结论血清miR-122单项检测在肝硬化、肝癌早期诊断中有一定价值,血清miR-122联合肿瘤标志物检测的诊断效能高于单一指标检测,本研究可为临床肝硬化、早期肝癌的检测提供参考。
OBJECTIVE To explore the diagnostic value of serum miR-122 combined with tumor markers in cirrhosis and early liver cancer in patients with chronic hepatitis B virus infection.METHODS Totally 65 patients,54 patients,and 52 patients with chronic hepatitis B,cirrhosis and early liver cancer,respectively,who were diagnosed and treated in Bincheng Municipal Hospital of Binzhou from Jul.2016 to Oct.2019 were selected as the research subjects.All patients were tested for serum tumor markers AFP(Alphafetoprotein,AFP),CEA(carcinoembryonic antigen,CEA)detection,and qPCR was used to detect the level of serum microRNA-122 levels.The value of the three indicators in the diagnosis of cirrhosis and early liver cancer were analyzed.RESULTS The levels of AFP and CEA in patients with liver cancer were(98.64±13.94)ng/ml and(28.86±2.05)ng/ml,respectively,significantly higher than those in patients with cirrhosis(34.60±11.84)ng/ml and(11.36±2.31)ng/ml,respectively and hepatitis B(18.38±8.39)ng/ml and(3.57±1.52)ng/ml,respectively(P<0.05).The levels of tumor markers in patients with liver cirrhosis were higher than those in patients with hepatitis B(P<0.05).The serum miR-122 in patients with liver cancer were significantly lower than that of patients with hepatitis B and cirrhosis(P<0.001),and the miR-122 in patients with liver cirrhosis were significently lower than that of patients with hepatitis B(P<0.001).The ROC curve results showed that the diagnostic efficacy of miR-122 combined with tumor marker detection for the diagnosis of liver cirrhosis(AUC:0.813;sensitivity:85.12%;specificity:70.18%)was significently higher than that of tumor marker and miR-122 alone(P<0.001).The diagnostic efficacy of miR-122 combined with tumor marker detection for early liver cancer diagnosis(AUC:0.866;sensitivity:91.23%;specificity:77.19%)was significently higher than that of tumor markers and miR-122 alone(P<0.001).CONCLUSION The single detection of serum miR-122 had certain value in the early diagnosis of liver cirrhosis and liver cancer.The
作者
吕金明
李燕
苏凤君
LYU Jin-ming;LI Yan;SU Feng-jun(Bincheng City Hospital,Binzhou City,Binzhou,Shandong256600,China;不详)
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2020年第19期2922-2926,共5页
Chinese Journal of Nosocomiology
基金
中关村国家自主创新示范区“重大前沿原创技术成果转化和产业化”基金资助项目(2019F000G113)。
